Abstract
In this review, the effect of peroxisome proliferator-activated receptor (PPAR) ligands on atherosclerosis is examined. The PPAR-γ agonist thiazolidinediones are currently indicated for the management of Type 2 diabetes mellitus, and the PPAR-α agonist fibrates are used in dyslipidaemia. Here their mechanism of action and the pre-clinical and clinical evidence for the use of these medications for the prevention and treatment of atherosclerotic disease is explored. In addition, the role of PPAR-δ and the possibilities for the role of dual-binding agonists are examined.
Original language | English (US) |
---|---|
Pages (from-to) | 1393-1403 |
Number of pages | 11 |
Journal | Expert Opinion on Investigational Drugs |
Volume | 13 |
Issue number | 11 |
DOIs | |
State | Published - Nov 1 2004 |
Keywords
- Atherosclerosis
- Coronary artery disease
- Fibrate
- PPAR
- Thiazolidinedione
ASJC Scopus subject areas
- Pharmacology